<DOC>
	<DOCNO>NCT01404117</DOCNO>
	<brief_summary>A multinational , multicenter , randomize , double-blind , parallel-group , placebo-controlled study ass safety , tolerability efficacy two daily dos oral laquinimod ( 0.6mg 1.2mg ) adjunct glatiramer acetate ( GA ) interferon-beta ( IFN-B ) relapse remit multiple sclerosis ( RRMS ) subject</brief_summary>
	<brief_title>A Multinational , Randomized , Double-blind , Parallel-group , Placebo-controlled Study Assessing Safety Tolerability</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1 . Subjects must document MS diagnosis define Revised McDonald criterion [ Ann Neurol 2011 : 69:292302 ] , relapsingremitting disease course . 2 . Subjects must ambulatory EDSS score 15.5 ( inclusive ) baseline visit . 3 . Subjects must relapsefree stable neurological condition free corticosteroid treatment [ intravenous ( IV ) , intramuscular ( IM ) and/or oral ] 30 day prior screen ( month 1 ) . 4 . Subjects must treat either Copaxone® IFNB preparation ( Avonex® , Betaseron®/Betaferon® , Rebif® Extavia® ) , stable dose least 6 month prior screen visit ( switch IFNB preparation 6 month prior screen allow ; switch IFNB preparation GA , vice versa , exclusionary ) . 5 . Subjects must experience least one document relapse 36 week prior randomization , incomplete recovery neurological function compare prerelapse status . 6 . Subjects must 18 55 year age , inclusive . 7 . Women childbearing potential must practice acceptable method birth control [ acceptable method birth control study include : surgical sterilization , intrauterine device , oral contraceptive , contraceptive patch , longacting injectable contraceptive doublebarrier method ( condom diaphragm spermicide ) ] . 8 . Subjects must able sign date write informed consent prior enter study . 9 . Subjects must willing able comply protocol requirement duration study . 1 . An onset relapse Month 1 ( Screening ) 0 ( Baseline ) , unstable neurological condition treatment corticosteroid [ intravenous ( IV ) , intramuscular ( IM ) and/or oral ] Adrenocorticotropic hormone . 2 . Use experimental investigational drug , and/or participation drug clinical study within 6 month prior Screening . 3 . Use immunosuppressive include Mitoxantrone ( Novantrone® ) cytotoxic agent within 6 month prior screen visit . 4 . Previous use either following : natalizumab ( Tysabri® ) , cladribine , laquinimod , fingolimod ( Gilenya® ) . 5 . Previous treatment intravenous immunoglobulin ( IVIG ) within 2 month prior screen visit . 6 . Systemic corticosteroid treatment ≥30 consecutive day duration within 2 month prior screen visit . 7 . Previous total body irradiation total lymphoid irradiation . 8 . Previous stem cell treatment , autologous bone marrow transplantation allogenic bone marrow transplantation . 9 . Use moderate/strong inhibitor cytochrome P450 CYP3A4 within 2 week prior screen visit . 10 . Use inducer CYP3A4 within 2 week prior screen visit . 11 . Use amiodarone within 2 year prior screen visit . 12 . Pregnancy breastfeed . 13 . A ≥3xULN serum elevation either alanine transaminase ( ALT ) aspartate transaminase ( AST ) screening . 14 . Serum direct bilirubin ≥2x upper limit normal ( ULN ) screening . 15 . Subjects potentially clinically significant unstable medical surgical condition would preclude safe complete study participation , determine medical history , physical examination , ECG , laboratory test chest Xray . Such condition may include ( limited ) : A cardiovascular pulmonary disorder wellcontrolled standard treatment permit study protocol . A gastrointestinal disorder may affect absorption study medication . Renal metabolic diseases Any form acute chronic liver disease Known human immunodeficiency virus ( HIV ) positive status A history drug and/or alcohol abuse An unstable psychiatric disorder . A known history tuberculosis . Unstable psychiatric disorder Any malignancy , exclude basal cell carcinoma ( BCC ) , last 5 year . 16 . A glomerular filtration rate le 60 ml/min screen visit . 17 . A known history sensitivity gadolinium ( Gd ) . 18 . Inability successfully undergo MRI scanning . 19 . Previous endovascular treatment Chronic Cerebrospinal Venous Insufficiency ( CCSVI ) . 20 . Known drug hypersensitivity would preclude administration laquinimod , hypersensitivity : mannitol , meglumine sodium stearyl fumarate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>